文献速递静脉血栓栓塞

重症COVID-19患者静脉血栓栓塞风险高

COVID-19 Infection in Critically Ill Patients Carries a High Risk of Venous Thrombo-embolism.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2020-12-23

这项队列研究纳入了2020年4月同一天入住ICU的230例重症COVID-19患者,在72小时内进行双下肢静脉多普勒超声筛查,并在7天随访时记录VTE事件和死亡。结果显示VTE总频率为26.5%(95%CI 21%-32%),其中DVT 45例、PE 16例;有症状VTE累积频率为8.3%(95%CI 4.7%-11.8%)。

要点

  • 重症COVID-19患者VTE总频率达26.5%,其中多数为无症状事件。
  • 接受抗凝治疗者仍可出现新发有症状VTE或复发。

核心结论

  • 重症COVID-19感染患者VTE风险高,即使接受抗凝治疗仍可能发生新发有症状VTE和复发。

研究设计与样本

  • 队列研究,纳入2020年4月同一天入住ICU的230例重症COVID-19患者,不论住院时间长短。
  • 在入组后72小时内进行单次双下肢静脉多普勒超声筛查,PE通过CT血管造影诊断。

主要发现

  • 7天随访时VTE(症状性和无症状性)频率为26.5%(95%CI 21%-32%),共61例患者发生69次事件:45例DVT,16例PE(其中8例合并DVT)。
  • 有症状VTE累积频率为8.3%(95%CI 4.7%-11.8%)。
  • 筛查后随访期间6例患者出现新发VTE,其中3例在筛查诊断DVT后尽管接受治疗剂量肝素仍复发。
  • 7天随访死亡率在VTE患者(6.6%)与无VTE患者(5.3%)之间相同。

关键数值与推荐

  • 对于出血风险低的患者,预防性抗凝剂量可能需要增加。

临床怎么用

  • 对重症COVID-19患者应警惕VTE,包括无症状事件,可考虑进行静脉超声筛查。
  • 接受抗凝治疗的患者仍需监测新发有症状VTE或复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The coronavirus disease of 2019 (COVID-19) due to SARS-CoV-2 infection has been found to cause an increased risk of venous thrombo-embolism (VTE). The aims of the study were to determine the frequency of VTE in critically ill patients with COVID-19 and its correlation with D dimer levels and pharmacological prophylaxis. METHODS: This was a cohort study of critically ill patients due to COVID-19. All patients admitted to the intensive care unit on the same day of April 2020 were selected, regardless of length of stay, and a single bilateral venous duplex ultrasound in the lower extremities was performed up to 72 hours later. Pulmonary embolism (PE) was diagnosed by computed tomography angiography. Asymptomatic and symptomatic VTE were registered, including pre-screening in hospital VTE. Characteristics of patients, blood test results, doses of thromboprophylaxis received, VTE events, and mortality after seven day follow up were recorded. RESULTS: A total of 230 critically ill patients were studied. The median intensive care unit stay of these patients was 12 days (interquartile range [IQR] 5 - 19 days). After seven days follow up, the frequency of patients with VTE, both symptomatic and asymptomatic, was 26.5% (95% confidence interval [CI] 21% - 32%) (69 events in 61 patients): 45 with DVT and 16 with PE (eight of them with concomitant DVT). The cumulative frequency of symptomatic VTE was 8.3% (95% CI 4.7% - 11.8%). D dimer values ≥ 1 500 ng/mL were diagnostic of VTE, with a sensitivity of 80% and a specificity of 42%. During follow up after screening, six patients developed new VTE. Three of them developed a recurrence after a DVT diagnosed at screening, despite receiving therapeutic doses of heparin. Mortality rates at seven day follow up were the same for those with (6.6%) and without (5.3%) VTE. CONCLUSION: Patients with severe COVID-19 infection are at high risk of VTE, and further new symptomatic VTE events and recurrence can occur despite anticoagulation. The prophylactic anticoagulant dose may need to be increased in patients with a low risk of bleeding.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Bellmunt-Montoya S, Riera C, Gil D, et al. COVID-19 Infection in Critically Ill Patients Carries a High Risk of Venous Thrombo-embolism. Eur J Vasc Endovasc Surg. 2020. PMID: 33583710. doi:10.1016/j.ejvs.2020.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。